European Alternatives to Biofourmis
Looking for a European alternative to Biofourmis? Its website is owned and operated by Biofourmis Inc., it announced a merger with the US company CopilotIQ on 21 October 2024, and its privacy policy has to name representatives in The Hague and the UK for European data subjects.
The European tools below cover home monitoring from Dutch, Finnish, Swedish, Belgian, German and British vendors that contract inside Europe, with programme libraries, white-label platforms and managed virtual wards.
How we rank these tools — 4-step process
-
1
European ownership, verified
The company is headquartered and incorporated in the EU, EEA, the UK, Switzerland or Israel, and processes customer data in Europe or Israel. A US parent company disqualifies a tool from this page regardless of where its servers are.
-
2
Category fit and hands-on review
What the tool actually does, who it suits, and where it falls short — checked against the vendor’s own documentation, changelog and pricing page rather than its marketing copy.
-
3
Compliance and pricing check
GDPR posture, hosting location and the prices quoted on this page are verified against the vendor’s public pricing before publication, and re-checked when we revisit the category.
-
4
Position on this page
Placement on this page can be paid, and that can affect which tools appear here and the order they appear in. It never buys a good review: a tool that fails the checks above is not here at any price, and payment does not change the shortcomings we write about. A vendor can ask us to correct a factual error — not to remove a criticism.
Vendors can pay for visibility on this page. It never changes what an entry says about a product, including the criticism, and we earn nothing when you click through to a vendor. Vendors can pay for more visibility, higher up on the review pages; it never affects which tools are listed. Editorial policy
12 European Alternatives to Biofourmis
Healthentia
Class IIa software for monitoring, coaching and trial data
Medixine
Configurable monitoring suite with a Bluetooth hub app
Cuviva
White-label platform with Swedish storage options
Luscii
Home monitoring programmes for 150+ conditions
Corsano Health
Medical wristband with cloud and raw data access
Dignio
Patient, clinician and care-home apps with dispensers
Doccla
Virtual wards with devices, logistics and clinicians
Qurasoft
SaniQ telemedicine platform for practices and clinics
SEMDATEX
Cardiac telemonitoring with implant and ECG data
Huma
Virtual wards on a broad health operating system
Medisanté
Cellular medical IoT cloud for monitoring devices
Cardiomatics
Browser-based AI analysis of Holter ECG recordings
Key takeaways
- Biofourmis announced a merger with CopilotIQ on 21 October 2024, and the combined company is led by David Koretz.
- The Biofourmis website is operated by Biofourmis Inc, and its terms send disputes to AAA arbitration in Massachusetts.
- Biofourmis names a Bird & Bird office in The Hague as its GDPR representative for the EEA and one in London for the UK.
- Luscii (Netherlands), Medixine (Finland), Cuviva (Sweden) and Healthentia (Belgium) all contract through EU entities, and Cuviva states storage options that exclude US providers.
- None of the twelve European tools on this page publishes prices, so a comparison with Biofourmis has to start from quotes.
Why people leave Biofourmis
Biofourmis sells software and services that let a hospital, health system or payor follow patients at home after surgery, during an acute episode or with a chronic condition. Its own website is operated by Biofourmis Inc, and its terms of service route disputes to arbitration in Massachusetts under American Arbitration Association rules. For a European health organisation that is the first thing to read, because a monitoring contract is a contract about patient data and clinical responsibility.
The company changed shape in October 2024, when it announced a merger with the US company CopilotIQ under a single chief executive, David Koretz.
The press release describes the result as one vendor for the whole care continuum, from pre-surgical optimisation to chronic care, with one integration and one security audit. That pitch suits a US payor with a Medicare-style population. A hospital in Utrecht or a municipality in Sweden buys differently, through national frameworks, local reimbursement rules and a procurement office that wants a contracting party inside the EU or EEA.
People therefore look beyond Biofourmis for reasons that are structural rather than a matter of product quality. The platform is aimed at enterprise customers in one market, the corporate story now centres on American older adults and in-home services, and the legal documents on the site were written for a US company that needed a named representative in The Hague and London for European data subjects.
- A US contracting party and a US dispute forum The terms of service on biofourmis.com say the site is run by Biofourmis Inc and its affiliates, and that unresolved disputes go to binding arbitration under AAA commercial rules, held in Massachusetts and in English. That text governs the website, and an enterprise contract can differ. Still, a European buyer who wants the vendor, the court and the supervisory authority in the same legal area will find the twelve tools on this page easier to contract with: they are registered in the Netherlands, Finland, Sweden, Belgium, Germany, Poland, Norway, the UK or Switzerland.
- Europe is handled through a representative Biofourmis privacy policy tells people in the EEA to contact Bird & Bird GDPR Representative Services in The Hague, and people in the UK to contact its London office. That is the mechanism the GDPR requires from a non-EU company, and it is not a flaw. It does mean the policy names a representative rather than an EEA office, and the representative can only be contacted for data protection queries, as the policy itself says.
- The business moved towards the American in-home market The 2024 release describes CopilotIQ as a company serving older Americans with chronic conditions, combining biomarker data with US-licensed nursing visits. Biofourmis Care and Biofourmis Connect are the two product lines it names for hospitals, health systems, payors and life-science sponsors. A buyer outside the US has to ask how much of that roadmap is built around US licensing, US reimbursement and US nursing networks, and how much will be offered in Europe.
- Public documents are old Both the privacy policy (9 September 2021) and the terms of service (1 September 2021) on the website carry dates from before the merger. Nothing in them is wrong because of that, but a procurement team comparing vendors on published documents will find a current privacy statement at Luscii (dated 23 March 2026) and readable terms or agreements at Healthentia, Luscii and Dignio, and will have to ask Biofourmis for the equivalents.
What you have to replace, not just match
Replacing Biofourmis means replacing a bundle, and the bundle depends on which side you used.
On the care-delivery side (Biofourmis Care) you used a platform that follows patients after surgery or discharge, with algorithms the company calls FDA-cleared, clinical workflows and the in-home services around them. In Europe the nearest match is a virtual-ward or home-monitoring platform such as Luscii, Doccla, Cuviva or Medixine, plus a clinical team of your own or from the vendor, because the nursing and logistics layer is not software.
On the life-science side (Biofourmis Connect) you used digital capture for clinical trials. Healthentia and Huma are the two tools on this page that state trial and decentralised-study use next to routine care, and both would need a protocol-specific validation before a sponsor moves a study over. Condition-specific replacements are narrower: SEMDATEX for heart failure and cardiac implants, Qurasoft for heart failure and COPD in Germany, and Cardiomatics for reading Holter ECGs.
Hardware and connectivity also need a decision. If the wearable or hub was part of the Biofourmis package, Corsano Health sells its own wristband, Medisanté supplies a vendor-neutral cellular device layer that feeds a platform you choose, and Medixine and Luscii work with long lists of third-party instruments. Write down every device, alarm rule and integration you rely on first, because those, not the dashboard, decide how long the move takes.
The alternatives compared
| Position | Tool | Headquarters | Pricing | Jurisdiction |
|---|---|---|---|---|
| #1 | Healthentia | Belgium (city not stated on pages reviewed), Belgium | Pricing on request | EU (Belgium) |
| #2 | Medixine | Espoo, Finland | Pricing on request | EU (Finland) |
| #3 | Cuviva | Gothenburg, Sweden | Pricing on request | EU (Sweden) |
| #4 | Luscii | Utrecht, Netherlands | Pricing on request | EU (Netherlands) |
| #5 | Corsano Health | The Netherlands (offices also in Switzerland), Netherlands | Pricing on request | EU (Netherlands) |
| #6 | Dignio | Norway, Norway | Pricing on request | EEA, not EU (Norway) |
| #7 | Doccla | London, United Kingdom | Pricing on request | United Kingdom (adequacy decision, outside the EEA) |
| #8 | Qurasoft | Koblenz, Germany | Pricing on request | EU (Germany) |
| #9 | SEMDATEX | Berlin, Germany | Pricing on request | EU (Germany) |
| #10 | Huma | London, United Kingdom | Pricing on request | United Kingdom (adequacy decision, outside the EEA) |
| #11 | Medisanté | Lucerne, Switzerland | Pricing on request | Switzerland (adequacy decision, outside the EEA) |
| #12 | Cardiomatics | Kraków, Poland | Pricing on request | EU (Poland) |
How each alternative compares to Biofourmis
Best for: Sponsors and hospitals that want one app for routine care and for studies, with the contract terms readable in advance.
Against Biofourmis, Healthentia is the smaller and more transparent option on documents. Innovation Sprint, a Belgian medtech manufacturer, publishes a Medical Device v4 class IIa MDR page, release notes and a SaaS agreement. That lets a procurement team read the terms before the first call, which the Biofourmis site does not offer for its product.
The scope resembles the Biofourmis split between care and trials: the same app covers remote monitoring, virtual coaching and decentralised clinical studies with patient-reported outcomes. The gap is in hospital operations. The pages we reviewed describe the patient app and the data layer, and say little about the logistics and clinician-service layer that a Biofourmis programme includes.
What Healthentia does better than Biofourmis
- Publishes its regulatory history and SaaS agreement for reading
- Contracts through a Belgian entity under EU law
- Combines care and trial capture in one app
- Separate material for heart failure and oncology reimbursement
Where Healthentia is a step down from Biofourmis
- No device logistics or clinical team described
- City, founding year and hosting location not stated
- No named large-scale hospital rollouts on the pages reviewed
Standout against Biofourmis. It is the only tool here that puts its SaaS agreement and MDR release history on public pages.
Best for: Care providers and device partners who want to configure the rules and brand the platform themselves.
Medixine compares with Biofourmis as a toolkit against a managed programme. Medixine Suite, released in 2015 by a company founded in 2000, lets a clinic set personal or population-wide alert limits and builds a ranked list of patients who need attention. The vendor states class IIa MDR certification and open APIs for partners.
Biofourmis brings its own algorithms and, since the merger, in-home services. Medixine brings neither, and its patient side is an Android hub app, with no ready-made library of disease programmes that we could verify. In return, a team of about 25 people in Espoo signs the contract under Finnish law, and the instrument list covers blood pressure, oximetry, spirometry, scales and an ECG recorder.
What Medixine does better than Biofourmis
- Alert limits you can set per patient or per population
- White label with open APIs for partners
- Finnish contracting entity with MDR class IIa stated
- Hub app means patients need no smartphone pairing
Where Medixine is a step down from Biofourmis
- No proprietary algorithms comparable to Biofourmis
- Patient hub app is Android only
- No library of disease programmes verified
Standout against Biofourmis. A hospital can rebrand the whole suite and add its own devices through open APIs.
Best for: Municipalities and regions that must prove where data is stored and who can reach it.
Cuviva answers the question Biofourmis leaves open, which is where the data sits. Its security page says customers can pick hybrid or local set-ups and, since moving to Kubernetes, storage with non-US providers based in Sweden. Data is pseudonymised and tied to an installation ID. Biofourmis privacy policy, by contrast, mentions a cloud provider with servers in various jurisdictions.
On certificates the two are close: Cuviva names an MDR class IIa certificate from BSI, ISO 13485:2016 and ISO 27001:2022, all stated by the vendor. Where Biofourmis is built for payors and hospital networks in the US, Cuviva is built for municipal home care and hospital-at-home, mostly in Scandinavia, so its references abroad are thinner and its documentation is Swedish first.
What Cuviva does better than Biofourmis
- States storage that excludes US providers
- Pseudonymised data tied to an installation ID
- Designed for municipal and regional home care
- MDR, ISO 13485 and ISO 27001 certificates named
Where Cuviva is a step down from Biofourmis
- Fewer references outside Scandinavia
- Swedish-first documentation
- Broad module list that needs scoping
Standout against Biofourmis. Its pages are the only ones in this set that describe choosing non-US storage.
Best for: Hospitals that want many pathways on one platform and have a FHIR-capable patient record.
Luscii is the tool that most closely mirrors the care-delivery side of Biofourmis. Where Biofourmis sells a continuum from pre-surgery to chronic care, Luscii offers more than 150 condition programmes and a Medical Developer route to write new ones, with 100+ devices and FHIR integration. Its Dutch home page claims use in 85 percent of hospitals and eleven countries; those are vendor numbers.
The difference is where the intelligence sits. Biofourmis stresses algorithms. Luscii routes a threshold breach through questions to the patient first, and reports that 34 percent of alarms in one COPD pathway at St. Antonius hospital are handled automatically. It publishes a privacy statement dated 23 March 2026 and separate terms for UK and US users, but not a price or a hosting location, and most product pages are in Dutch.
What Luscii does better than Biofourmis
- Larger library of ready condition programmes
- Alarms filtered through patient questions before a nurse sees them
- Terms published for UK and US users as well
- Utrecht entity with a recent privacy statement
Where Luscii is a step down from Biofourmis
- No proprietary clinical algorithms comparable to Biofourmis
- Hosting location and prices not published
- Most product pages are in Dutch
Standout against Biofourmis. It is the one European tool that lets clinicians write new condition programmes from templates.
Best for: Hospitals and researchers who want raw sensor data and a vendor-owned wearable.
Corsano Health matters if the wearable was the reason you chose Biofourmis. The company makes the CardioWatch 287, which streams ACC, PPG, ECG, temperature and GSR signals to its cloud, and offers a cuffless blood pressure algorithm. Researchers can pull raw PPG data through APIs and a portal, and an iOS and Android SDK keeps data in your own analytics platform.
Biofourmis packages devices, algorithms and services around a care programme. Corsano supplies the hardware, the cloud and early warning scores, then relies on hospital systems for the pathway. You are tied to its wristband, and the privacy policy mentions HIPAA next to GDPR, which tells you the company also serves US customers. The vendor states CE-MDR and FDA certification.
What Corsano Health does better than Biofourmis
- Raw PPG and ECG access through APIs and SDKs
- Hardware, cloud and warning scores from one vendor
- Dutch entity with a ward-monitoring use case
- Data can stay inside your own analytics platform
Where Corsano Health is a step down from Biofourmis
- Locked to Corsano hardware
- No condition programme library
- Hosting location and prices not published
Standout against Biofourmis. It is the only tool here that is a sensor maker first and a platform second.
Best for: Nordic municipalities and care homes that want medicine dispensers and vital-sign alerts in one view.
Dignio splits the work between three apps: MyDignio for patients, Dignio Prevent for clinicians and Prevent Go for residential care teams. Against Biofourmis, the notable difference is the care-home app and the electronic medicine dispensers, which push a missed dose into the same alert list as an abnormal reading. Biofourmis messaging focuses on hospitals, payors and life-science sponsors.
Dignio is a Norwegian company established in 2012, listing Norway, Sweden and Finland as locations, which puts it in the EEA but not the EU. It lists more than 20 integrated devices, fewer than Luscii. The English site is short, and its figure of 40,000 improved lives comes without a stated method, so treat it as marketing.
What Dignio does better than Biofourmis
- Dedicated app for residential care teams
- Medicine dispensers tied to the alert view
- Clinician-led device pairing, no patient set-up
- EEA-based vendor operating in three Nordic countries
Where Dignio is a step down from Biofourmis
- Fewer integrated devices than larger rivals
- No clinical-trial capture described
- Short English documentation, hosting not stated
Standout against Biofourmis. Medicine dispensing and vital-sign alerts share one clinician view.
Best for: Health systems that want to buy monitoring capacity rather than staff it internally.
Doccla is the closest European match for the service half of Biofourmis. Besides software it supplies connected devices, last-mile logistics and a clinical monitoring team of nurses, GPs and consultants under CQC registration. A hospital can contract for monitored patients instead of recruiting, which resembles what Biofourmis sells through its in-home services after the CopilotIQ merger.
The legal entity is Doccla UK Limited, so an EU buyer works with a UK company under an adequacy decision. The clinician dashboard page says Doccla Virtual Ward is sold in the UK, Virtual Care and VitalSync in the EU, and Doccla RPM is still in preparation. The homepage names operations in eleven European countries. Check the EU entity before you sign anything.
What Doccla does better than Biofourmis
- Devices, logistics and clinicians from one supplier
- Two-way links to SystmOne, Cerner and EMIS
- ISO 27001 stated, CQC registration published
- Operations across eleven European countries per its homepage
Where Doccla is a step down from Biofourmis
- UK-incorporated, outside the EEA
- EU products named differently, one still in preparation
- References centred on NHS pathways
Standout against Biofourmis. It sells monitored patients as a service, with its own clinicians behind the dashboard.
Best for: German practices, clinics and insurers running telemonitoring under national contracts.
Qurasoft, a software developer in Koblenz with a published commercial register entry (HRB 24744), splits its SaniQ platform by audience: HERZ for cardiology practices, CLINIC for hospital-at-home and myCOACH for insurers running prevention. Against Biofourmis, which sells one enterprise platform, this is a set of products shaped around German structures such as the COPD selective contract.
Its news page cites a Marburg study on post-COVID in children, the Telementor-COPD study, a GUIDE-AI consortium led by Charité and a partnership with the HDZ NRW institute. The site is German first, no founding year, device list, price or hosting location appears on the pages read, and use outside Germany would need checking.
What Qurasoft does better than Biofourmis
- Products matched to German practice, clinic and payer roles
- Research partnerships named with German institutes
- Commercial register data published
- Contracts under German law
Where Qurasoft is a step down from Biofourmis
- German-first site and German care logic
- Device list and founding year not published
- No trial-capture offer described
Standout against Biofourmis. It offers a COPD programme designed around a German selective contract.
Best for: Telemedicine centres and cardiologists tracking implant and heart failure patients across sites.
SEMDATEX narrows the Biofourmis scope to the heart. inCareNet HF combines data from ICD, CRT-D and CRT-P implants with external sensors and flags threshold breaches for a network of clinicians, while inPACE, launched in 2019, supports follow-up for implants from all manufacturers. Biofourmis spreads across surgery, acute and chronic care; SEMDATEX goes deeper into one specialty.
The company was founded in Berlin in 2017 and its imprint shows HRB 183526 B at the Charlottenburg court. It lists ISO 13485 and ISO/IEC 27001, and makes its own three-channel Holter, net_ECG, which records up to 12 days. Its pages disagree on size, 180+ telemonitoring centres in one place and 300+ medical centres in another, so ask for written figures.
What SEMDATEX does better than Biofourmis
- Implant data from all manufacturers in one view
- Own Holter ECG device up to 12 days
- Shared dashboard across telemedicine centres
- German entity with register data and ISO certificates
Where SEMDATEX is a step down from Biofourmis
- Cardiology only, no respiratory or diabetes pathways
- Reimbursement logic tied to German rules
- No trial-capture or payor offer described
Standout against Biofourmis. Implant telemetry and external sensors appear in the same clinician dashboard.
Best for: Health systems and governments planning many pathways and trial work under one vendor.
Huma is the nearest European counterpart to the scale of Biofourmis. It claims 450+ deployments, sells condition apps such as GDm Health for diabetes in pregnancy and Huma MG for myasthenia gravis, and covers care delivery and clinical trials. Like Biofourmis, it has US presence and regional offices spanning the UK, EU, Germany, the Middle East, APAC and South Africa.
The risk is the same as with Biofourmis: remote monitoring is now one use case inside a larger offer, which the home page calls an operating system for AI in regulated industries. Its efficacy figures, such as a 30 percent drop in readmissions, are self-reported. The website names Huma Therapeutics Limited as controller and refers to the ICO, so the contracting entity may be British rather than EU.
What Huma does better than Biofourmis
- Published transfer, regulatory and imprint disclosures
- Ready-made apps for specific conditions
- Presence in UK, EU and Germany
- Trials and care delivery on one platform
Where Huma is a step down from Biofourmis
- UK controller and a US office, so entity must be checked
- Remote monitoring is one use case among many
- Efficacy figures are the vendor's own
Standout against Biofourmis. It has the largest claimed deployment count of the European tools in this list.
Best for: Health IT and biomedical engineering teams that already run a monitoring platform.
Medisanté replaces only the plumbing under a programme like Biofourmis. M + Hub is described as a medical device data system: devices connect through cellular IoT directly to the cloud, with no consumer smartphone and no device-maker cloud on the path, then pass data to the platform the care team chooses. Biomedical engineers get a fleet view of battery level and signal strength of devices.
There is no clinician dashboard, no alert logic and no patient engagement, so you need a second platform, for example Medixine or Cuviva. The company is Medisanté Group AG in Lucerne, Switzerland, which contracts outside the EU and EEA, though under an EU adequacy decision. Terms, privacy pages and hosting location were not read, and a Vodafone IoT executive is quoted on its Solutions page.
What Medisanté does better than Biofourmis
- Vendor-neutral device layer, not tied to one platform
- Fleet monitoring of battery and signal strength
- No patient smartphone in the data path
- Swiss impressum names the legal entity
Where Medisanté is a step down from Biofourmis
- No clinical dashboard or alerting
- Needs a second platform to be useful
- Contracts outside the EU and EEA
Standout against Biofourmis. It treats the connected device, not the dashboard, as the product.
Best for: Cardiology clinics and device makers who need faster Holter ECG interpretation.
Cardiomatics covers a narrow slice of what Biofourmis sells: reading ECGs. A clinician uploads a raw Holter signal to the browser-based platform, which works with more than 60 devices and returns an editable report. Against a monitoring programme that streams vitals from a patient at home, this is a diagnostic step performed after a recording.
The legal page names Cardiomatics Sp. z o.o. in Kraków, a Polish company with a published registration, and the vendor states ISO 27001. It says its atrial fibrillation assessment was validated in a study with University Hospital Basel, which we did not open, so that is a claim to check. It collects no blood pressure, weight or symptoms, and has no patient app.
What Cardiomatics does better than Biofourmis
- Works with 60+ Holter devices without installation
- Editable report instead of manual annotation
- Partner route for device makers
- Polish entity with published registration
Where Cardiomatics is a step down from Biofourmis
- ECG analysis only, no patient-facing app
- Cannot replace a monitoring platform on its own
Standout against Biofourmis. It is the only tool here built for ECG interpretation instead of patient follow-up.
What actually breaks when you switch
The hardest part of leaving Biofourmis is the data you do not control. Ask in writing what can be exported at contract end: patient records, measurement history, alarm logs and the configuration of thresholds.
The privacy policy on the website covers site visitors only, so the answer sits in your contract and data processing agreement. Plan the export format with the new vendor, since Luscii works with FHIR and Medixine with open APIs, and map identifiers so a patient keeps one history across both systems.
People are the second cost. Nurses who triage alarms need retraining on a new dashboard, patients may have to change devices or apps, and any home visits or logistics Biofourmis provided must be covered by someone. Also check the exit terms: the terms on its website send disputes to arbitration in Massachusetts, and a hospital contract may differ, so read what notice period and what transition support apply. Run one pathway in parallel before moving the rest.
Does leaving Biofourmis change who is the medical device manufacturer?
It can. Biofourmis presents its algorithms as FDA-cleared, which is a US status. In the EU the equivalent is the CE mark under the MDR, and the vendor you move to has to hold it for the intended use.
Medixine, Cuviva and Healthentia state MDR class IIa for their software, and Luscii describes its product as CE class IIa; Corsano states CE-MDR and FDA for its wristband. All of these are vendor statements, so ask for the certificate and its scope.
The consequence for you is regulatory paperwork. As the deploying organisation you will want the certificate number, the intended-use statement, the notified body and the instructions for use. Healthentia publishes a release history and a SaaS agreement, which shortens that step. For a vendor that does not publish them, make delivery of the documents a condition of the pilot.
Can a European tool take over a programme that Biofourmis runs for a hospital?
For software and alarms, yes. Luscii lists more than 150 condition programmes and a builder for your own, Medixine offers personal and population-wide alert limits, and Cuviva covers hospital-at-home as well as municipal home care. The parts that do not transfer are the proprietary algorithms and anything the Biofourmis team delivers as a service. Those must be rebuilt as clinical protocols that your own staff or a vendor service, such as the Doccla monitoring team, operate.
Run the two systems in parallel on one pathway for a few weeks before switching the rest. Compare alert volume, false alarms and time spent by nurses per patient. Luscii reports that 34 percent of alarms in a COPD pathway at one Dutch hospital are handled automatically, and Huma quotes figures on readmissions and review time; both are vendor numbers, so measure your own.
Which one to pick
For a hospital that mainly wants software and many pathways, start with Luscii, then compare Medixine and Cuviva if white labelling or storage control matter more. Choose Cuviva when you must name the storage provider, and Medixine when you want to set your own alert rules. If you also need devices, logistics and monitoring nurses, Doccla is the service-style option, with the UK entity caveat. For trials and routine care on one app, Healthentia and Huma are the candidates.
Specialty cases split off. SEMDATEX and Qurasoft suit German cardiology and COPD networks, Cardiomatics adds ECG reading, Corsano Health fits if the wristband is the reason, Dignio fits Nordic care homes, and Medisanté fits when you already own the platform and need connectivity. Stay with Biofourmis if your population is American, your contract is with the US entity and you rely on its FDA-cleared algorithms, because none of the twelve tools here replaces that regulatory status.
Frequently Asked Questions
By breadth of programmes and hospital integration, Luscii is the closest match among the European tools here, with 150+ condition programmes, 100+ devices and a FHIR link to the patient record. If you need a virtual ward with devices and clinicians supplied, look at Doccla. For white-label platforms with an MDR certificate, look at Medixine and Cuviva. Which is best depends on whether you buy software only or a service.
Its privacy policy names an EEA representative in The Hague and a UK representative in London, which is what the GDPR asks of a company outside the EU. That policy covers visitors to the website and was last updated in September 2021. Whether a hospital contract meets your requirements depends on the data processing agreement, the processing locations and the sub-processors, none of which are published on the site. Ask for them in writing.
No. All twelve tools on this page list pricing on request, and Biofourmis does not publish prices on the pages we read either. Expect a quote that depends on patient numbers, devices and whether clinicians are supplied. For a fair comparison, give each vendor the same scenario: patients per month, condition, device kit, monitoring hours and integration with your electronic record.
Only Cuviva states a choice on its pages: customers can run hybrid or local set-ups and choose storage with non-US providers based in Sweden. The other tools do not state a hosting location on the pages we reviewed, so ask. Huma publishes an international data transfer disclosure, and Doccla and Huma are UK entities, which the EU treats under an adequacy decision rather than as members of the EEA.
Yes. Cardiomatics covers ECG interpretation only, SEMDATEX covers cardiac implants and heart failure, and Medisanté supplies the connected-device layer without a clinical dashboard. Many organisations keep a general platform and swap a single pathway first. The risk is two vendors for one patient, so settle which system holds the clinical record and which one sends alerts before you start.
Related comparisons
About the author
Explore More European Alternatives
Discover privacy-focused European alternatives to other popular US tech services.